WebOct 31, 2024 · GB1211 significantly reduced all measures of inflammation, fibrosis and fat compared to the control group. There were also trends for reduction in fibrotic and galectin-3 mechanistic genes (COL1A1 ... WebGB1211 is also being studied in pts with hepatic impairment (NCT05009680). Trial design GALLANT-1 is a 3-part phase 1b/2a study that will investigate safety and efficacy of GB1211 + atz vs placebo + atz in pts with advanced or metastatic NSCLC that expresses PD-L1 on ≥50% of tumour cells.
Safety and pharmacokinetics of GB1211, an oral galectin-3
WebGB1211 (Galecto Biotech) is an oral galectin-3 inhibitor under development for fibrotic disease. First described in 1971, galectin-3, a unique subtype of a 15-member family of … WebJun 16, 2024 · GB1211 is designed to counter these effects. GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and exhibited dose-dependent pharmacokinetics. thom meyers
ESMO Congress OncologyPRO
WebJan 18, 2024 · GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A … WebDec 13, 2024 · GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and had dose-dependent pharmacokinetics. About Galectin-3 in Liver Cirrhosis WebApr 14, 2024 · Delhi, April 14, 2024 (GLOBE NEWSWIRE) -- Global Galectin Inhibitors Market Trends & Clinical Trials Insight 2024 Report Highlights: Global Galectin Inhibitors Clinical Pipeline By Company ... ukrainian language flash cards